Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD

Not Applicable

Not yet recruiting

• Conditions: Obsessive-Compulsive Disorder
• Interventions: Device: Virtual Reality

• Registration Number: NCT06442527
• Lead Sponsor: Yale University

Brief Summary

This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-05-29
• Study First Submitted QC: 2024-05-29
• Study First Posted: 2024-06-04
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-06
• Last Update Posted: 2025-03-07
• Study Start: 2025-05
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Participants must be at least 18 years old
• Patients must have been clinically evaluated by a Yale Interventional Psychiatry Service physician who has deemed them appropriate to receive TMS for the treatment of OCD
• Ability and willingness, in the investigator's judgement, to comply with the study procedure and study requirements.

Exclusion Criteria

• Hearing or visual impairment to the degree that would interfere with ability to see or hear VR content.
• Difficulty in understanding spoken or written English
• Pregnancy
• History of seizure disorder
• Unable to provide informed consent
• Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the study procedure (per investigator judgment)
• Any implanted medical device, risk of interference with which by the VR device in the investigator's judgment can put patient at additional undue risk.
• Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study.
• Was previously enrolled/randomized into the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment Group	Virtual Reality	This single arm will include all participants of the study, who will all receive the intervention

Primary Outcome Measures

Name	Time	Method
Tolerability of VR treatment by qualitative assessment	Within 1 hour after each treatment session	Tolerability will be assessed by open-ended interview of the patient about their experience and any difficulty tolerating VR

Trial Locations

Locations (1)

Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit; 🇺🇸 New Haven, Connecticut, United States